Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

EVITA Vitamin C Blood Cancer Trial

Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 23, 2026

Sentiment
5
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The results are an early-stage signal rather than proof, so they are unlikely to move broad markets or large pharmaceutical valuations in the near term. They could modestly support sentiment for vitamin and supplement makers and for companies pursuing blood cancer interception therapies, while reinforcing caution that phase 2 findings often fail in phase 3.

pharmaceuticals healthcare biotechnology

The phase 2 EVITA trial, a randomized, double-blind, placebo-controlled study, tested whether high-dose oral vitamin C (1000 mg/day for 12 months) could benefit patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies, conditions that can progress to blood cancers such as leukemia. The trial enrolled 109 patients in Denmark and the United States, with 55 assigned to vitamin C and 54 to placebo. The primary endpoint, growth rate of precancerous or cancerous cells, showed no meaningful difference between groups. However, participants receiving vitamin C showed changes in inflammatory signaling consistent with better outcomes, and anemia, pneumonia, acute aseptic arthritis, and internal bleeding were less frequent, though gastrointestinal problems were more common. At a median follow-up of 33.6 months, 35 deaths occurred: 24 in the placebo group and 11 in the vitamin C group, according to an exploratory analysis that suggested better survival among those assigned vitamin C. Researchers, including Peter A. Jones of Van Andel Institute and Kirsten Green of Rigshospitalet, Copenhagen University Hospital, cautioned that the survival finding requires confirmation in a larger phase 3 trial and that it is too soon to recommend vitamin C for these patients. Results were published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. The trial was led by the Van Andel Institute-Stand Up to Cancer Epigenetics Dream Team.

70 Van Andel Institute led trial
50 American Cancer Society published trial results
50 Wiley (publisher) published trial results
40 Stand Up to Cancer led trial
ngo
Co-led the EVITA trial through its VAI-SU2C Epigenetics Dream Team and provided co-senior author Peter A. Jones; the positive exploratory signal enhances its research reputation.
Importance 85.0 Sentiment 10.0
per
Co-senior author of the EVITA trial who voiced cautious optimism about vitamin C for intercepting leukemia development.
Importance 70.0 Sentiment 5.0
per
Co-senior author of the trial who emphasized that larger studies are needed before recommendations can be made.
Importance 70.0 Sentiment 5.0
ngo
Its VAI-SU2C Epigenetics Dream Team helped lead the trial, supporting its mission of accelerating cancer research.
Importance 60.0 Sentiment 6.0
ngo
Its peer-reviewed journal CANCER published the trial results, reinforcing its role as a disseminator of oncology research.
Importance 55.0 Sentiment 5.0
stock
Published the EVITA trial results online in CANCER, adding a notable oncology study to its publishing portfolio.
Importance 45.0 Sentiment 3.0
cnt
One of two countries where the 109-patient EVITA trial enrolled participants, contributing to the study's clinical research base.
Importance 30.0 Sentiment 2.0
cnt
One of two countries where the trial enrolled participants, contributing to the study's clinical research base.
Importance 30.0 Sentiment 2.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.